Antipsychotics at Doses >75 mg a Day Linked to Risk for Tardive Dyskinesia
By Elana Gotkine HealthDay Reporter
FRIDAY, Jan. 17, 2025 -- Antipsychotics at doses >75 mg/day are associated with an increased risk for tardive dyskinesia (TD), according to a study recently published in the Journal of Clinical Psychopharmacology.
Maki Gouda, from the Mitsubishi Tanabe Pharma Corporation in Osaka, Japan, and colleagues examined the association between antipsychotic doses and the risk for TD in clinical practice in a population of patients aged 15 years or older with a diagnosis of schizophrenia, depression, or bipolar disorder. Patients newly diagnosed with TD were categorized as cases and were matched with a control group in a 1:10 ratio.
The analysis population included 58,452 patients; 80 of these patients were identified as TD cases. The researchers found that doses >75 mg/day at the last prescription and as the maximum dose before the date of TD diagnosis were associated with a significantly increased risk for TD. In post-hoc analyses, there was a significant association between doses ≥300 mg/day versus ≤75 and >75 to <300 mg/day and the risk for TD. The odds ratios were 3.40 and 3.50 when comparing ≥300 mg/day with >75 to <300 mg/day at the last prescription and as the maximum dose before first diagnosis of TD, respectively.
"The prescription of high dose was associated with an increased risk of TD, and the highest risk was observed in the group receiving >300 mg/day," the authors write. "Therefore, it is crucial to consider the potential risks of TD and to carefully monitor patients receiving antipsychotic treatment."
Several authors disclosed ties to pharmaceutical companies, including the Mitsubishi Tanabe Pharma Corporation, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Alopecia Areata Associated With Severe Psychosocial Impact
THURSDAY, July 24, 2025 -- Alopecia areata (AA) has a severe psychosocial impact, which is linked to illness perceptions and stigma more strongly than disease severity, according...
Few School Principals Report District-Mandated Mental Health Screening
THURSDAY, July 24, 2025 -- Few school principals report district-mandated mental health screening in schools, according to a study published online July 18 in JAMA Network...
Cancer Anxiety Impacts Family Members of Those Diagnosed With Cancer
WEDNESDAY, July 23, 2025 -- A cancer diagnosis places an emotional burden on the loved ones of those diagnosed, according to the results of a survey released by the Ohio State...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.